Crospon receives CE Mark for EndoFLIP System

31 January 2009

Irish medical device developer Crospon has announced that its EndoFLIP system has received CE Mark certification from the NSAI (National Standards Authority of Ireland), the Irish Notified Body, in accordance with the European Medical Device Directive.

Crospon Limited develops minimally invasive medical devices for monitoring, diagnosis and therapy for gastroenterology. EndoFLIP is a diagnostic tool for assessing the competence of the gastroesophageal junction in patients with gastroesophageal reflux disease (GERD).

John O’Dea, CEO Crospon Ltd, said, “Today’s announcement is an important step in the company’s development and ensures Crospon remains on schedule to release the EndoFLIP system into the European market by the end of the first quarter of 2009.”

In December 2008, Crospon announced that it had completed an additional €500,000 funding round, following on from the completion of a €3m round of financing earlier that year. It says that this additional funding will be primarily used for the completion of development, manufacturing startup and preparation to market of the EndoFLIP system.

EndoFLIP is used to enhance diagnosis and assist in the surgical treatment of gastroesophageal reflux disorder (GERD). The EndoFLIP system is the first is a range of products the company plans to bring to market.

Bookmark this page

Your browser does not support inline frames or is currently configured not to display inline frames.	Your browser does not support inline frames or is currently configured not to display inline frames. Crospon receives CE Mark for EndoFLIP System 31 January 2009 Irish medical device developer Crospon has announced that its EndoFLIP system has received CE Mark certification from the NSAI (National Standards Authority of Ireland), the Irish Notified Body, in accordance with the European Medical Device Directive. Crospon Limited develops minimally invasive medical devices for monitoring, diagnosis and therapy for gastroenterology. EndoFLIP is a diagnostic tool for assessing the competence of the gastroesophageal junction in patients with gastroesophageal reflux disease (GERD). John O’Dea, CEO Crospon Ltd, said, “Today’s announcement is an important step in the company’s development and ensures Crospon remains on schedule to release the EndoFLIP system into the European market by the end of the first quarter of 2009.” In December 2008, Crospon announced that it had completed an additional €500,000 funding round, following on from the completion of a €3m round of financing earlier that year. It says that this additional funding will be primarily used for the completion of development, manufacturing startup and preparation to market of the EndoFLIP system. EndoFLIP is used to enhance diagnosis and assist in the surgical treatment of gastroesophageal reflux disorder (GERD). The EndoFLIP system is the first is a range of products the company plans to bring to market. Bookmark this page Your browser does not support inline frames or is currently configured not to display inline frames. To top	Your browser does not support inline frames or is currently configured not to display inline frames.